Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Omnicom Group Inc. — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Omnicom Group Inc. trades at $76.35 (market cap $20.54B). The key difference: Omnicom Group Inc. is far larger — about 12× Nuvation Bio Inc. Class A Common Stock's market cap, and Omnicom Group Inc. pays a 4.27% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Omnicom Group Inc. for 63 Days on average.
| NUVB | OMC | |
|---|---|---|
Market Cap | $1.71B | $20.54B |
Volume | 5,448,712 | 1,803,209 |
Sector | Health | Media |
52-Week High | $9.54 | $88.94 |
52-Week Low | $3.41 | $67.27 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $1.30B | $28.62B |
Dividend Yield | — | 4.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OMC trades at $76.45, up 1.8% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, though 2026 projections show a return to profitability. Recent news highlights leadership in digital marketing and significant new business wins, including $3.3 billion in H1 2026 billings.
The stock presents a value opportunity with a low P/S of 0.84 and a consensus price target of $104.67, implying 37% upside. However, high P/E of 202.35, recent net loss, and advertising market volatility pose risks. Analyst sentiment is cautious with 59% hold ratings, reflecting balanced near-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
